Epidemiological findings of vascular risk factors in Alzheimer’s disease: implications for therapeutic and preventive intervention

References

• Fratiglioni L, Launer LJ, Andersen K et al. Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurology54(11 Suppl. 5), S10–S15 (2000).
   PubMed Web of Science ®Google Scholar
• Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat. Rev. Neurol.7, 137–152 (2011).
   PubMed Web of Science ®Google Scholar
• Breteler MM. Vascular risk factors for Alzheimer’s disease: an epidemiologic perspective. Neurobiol. Aging21, 153–160 (2000).
   PubMed Web of Science ®Google Scholar
• Geldmacher DS. Alzheimer disease prevention: focus on cardiovascular risk, not amyloid? Cleve. Clin. J. Med.77, 689–704 (2010).
   PubMedGoogle Scholar
• Stanziano DC, Whitehurst M, Graham P, Roos BA. A review of selected longitudinal studies on aging: past findings and future directions. J. Am. Geriatr. Soc.58(Suppl. 2), S292–S297 (2010).
   PubMed Web of Science ®Google Scholar
• Qiu C, Xu W, Fratiglioni L. Vascular and psychosocial factors for Alzheimer’s disease: epidemiological evidence toward intervention. J. Alzheimers Dis.20, 689–697 (2010).
   PubMed Web of Science ®Google Scholar
• Barnes DE, Haight TJ, Mehta KM, Carlson MC, Kuller LH, Tager IB. Secondhand smoke, vascular disease, and dementia incidence: findings from the Cardiovascular Health Cognition Study. Am. J. Epidemiol.171, 292–302 (2010).
   PubMedGoogle Scholar
• Anstey KJ, von Sanden C, Salim A, O’Kearney R. Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. Am. J. Epidemiol.166, 367–378 (2007).
   PubMed Web of Science ®Google Scholar
• Peters R, Poulter R, Warner J, Beckett N, Burch L, Bulpitt C. Smoking, dementia and cognitive decline in the elderly: a systematic review. BMC Geriatr.8, 36 (2008).
   PubMedGoogle Scholar
• Cataldo JK, Prochaska JJ, Glantz SA. Cigarette smoking is a risk factor for Alzheimer’s disease: an analysis controlling for tobacco industry affiliation. J. Alzheimers Dis.19, 465–480 (2010).
   PubMed Web of Science ®Google Scholar
• Rusanen M, Rovio S, Ngandu T et al. Midlife smoking, apolipoprotein E and risk of dementia and Alzheimer’s disease: a population-based Cardiovascular Risk Factors, Aging and Dementia study. Dement. Geriatr. Cogn. Disord.30, 277–284 (2010).
   PubMedGoogle Scholar
• Rusanen M, Kivipelto M, Quesenberry CP Jr, Zhou J, Whitmer RA. Heavy smoking in midlife and long-term risk of Alzheimer disease and vascular dementia. Arch. Intern. Med.171, 333–339 (2011).
   PubMedGoogle Scholar
• Alonso A, Jacobs DR Jr, Menotti A et al. Cardiovascular risk factors and dementia mortality: 40 years of follow-up in the Seven Countries Study. J. Neurol. Sci.280(1–2), 79–83 (2009).
   PubMedGoogle Scholar
• Hernán MA, Alonso A, Logroscino G. Cigarette smoking and dementia: potential selection bias in the elderly. Epidemiology19, 448–450 (2008).
   PubMedGoogle Scholar
• Tyas SL, White LR, Petrovitch H et al. Mid-life smoking and late-life dementia: the Honolulu-Asia Aging Study. Neurobiol. Aging24, 589–596 (2003).
   PubMed Web of Science ®Google Scholar
• Anttila T, Helkala EL, Viitanen M et al. Alcohol drinking in middle age and subsequent risk of mild cognitive impairment and dementia in old age: a prospective population based study. BMJ329, 539 (2004).
   PubMed Web of Science ®Google Scholar
• Peters R, Peters J, Warner J, Beckett N, Bulpitt C. Alcohol, dementia and cognitive decline in the elderly: a systematic review. Age Ageing37, 505–512 (2008).
   PubMed Web of Science ®Google Scholar
• Anstey KJ, Mack HA, Cherbuin N. Alcohol consumption as a risk factor for dementia and cognitive decline: meta-analysis of prospective studies. Am. J. Geriatr. Psychiatry17, 542–555 (2009).
   PubMed Web of Science ®Google Scholar
• Larson EB, Wang L, Bowen JD et al. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann. Intern. Med.144, 73–81 (2006).
   PubMed Web of Science ®Google Scholar
• Scarmeas N, Luchsinger JA, Brickman AM et al. Physical activity and Alzheimer disease course. Am. J. Geriatr. Psychiatry19, 471–481 (2011).
   PubMed Web of Science ®Google Scholar
• Scarmeas N, Luchsinger JA, Schupf N et al. Physical activity, diet, and risk of Alzheimer disease. JAMA302, 627–637 (2009).
   PubMed Web of Science ®Google Scholar
• Hamer M, Chida Y. Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence. Psychol. Med.39, 3–11 (2009).
   PubMed Web of Science ®Google Scholar
• Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol.4, 487–499 (2005).
   PubMed Web of Science ®Google Scholar
• Alonso A, Mosley TH, Gottesman RF, Catellier D, Sharrett AR, Coresh J. Risk of dementia hospitalisation associated with cardiovascular risk factors in midlife and older age: the Atherosclerosis Risk in Communities (ARIC) study. J. Neurol. Neurosurg. Psychiatry80, 1194–1201 (2009).
   PubMed Web of Science ®Google Scholar
• Launer LJ, Hughes T, Yu B et al. Lowering midlife levels of systolic blood pressure as a public health strategy to reduce late-life dementia: perspective from the Honolulu Heart Program/Honolulu Asia Aging Study. Hypertension55, 1352–1359 (2010).
   PubMed Web of Science ®Google Scholar
• Bermejo-Pareja F, Benito-León J, Louis ED et al. Risk of incident dementia in drug-untreated arterial hypertension: a population-based study. J. Alzheimers Dis.22, 949–958 (2010).
   PubMedGoogle Scholar
• Qiu C, Winblad B, Fratiglioni L. Low diastolic pressure and risk of dementia in very old people: a longitudinal study. Dement. Geriatr. Cogn. Disord.28, 213–219 (2009).
   PubMed Web of Science ®Google Scholar
• Li G, Rhew IC, Shofer JB et al. Age-varying association between blood pressure and risk of dementia in those aged 65 and older: a community-based prospective cohort study. J. Am. Geriatr. Soc.55, 1161–1167 (2007).
   PubMed Web of Science ®Google Scholar
• Johnson KC, Margolis KL, Espeland MA et al. A prospective study of the effect of hypertension and baseline blood pressure on cognitive decline and dementia in postmenopausal women: the Women’s Health Initiative Memory Study. J. Am. Geriatr. Soc.56, 1449–1458 (2008).
   PubMedGoogle Scholar
• Euser SM, van Bemmel T, Schram MT et al. The effect of age on the association between blood pressure and cognitive function later in life. J. Am. Geriatr. Soc.57, 1232–1237 (2009).
   PubMedGoogle Scholar
• Kennelly SP, Lawlor BA, Kenny RA. Blood pressure and the risk for dementia: a double edged sword. Ageing Res. Rev.8, 61–70 (2009).
   PubMedGoogle Scholar
• Novak V, Hajjar I. The relationship between blood pressure and cognitive function. Nat. Rev. Cardiol.7, 686–698 (2010).
   PubMed Web of Science ®Google Scholar
• Rosengren A, Skoog I, Gustafson D, Wilhelmsen L. Body mass index, other cardiovascular risk factors, and hospitalization for dementia. Arch. Intern. Med.165, 321–326 (2005).
   PubMed Web of Science ®Google Scholar
• Beydoun MA, Lhotsky A, Wang Y et al. Association of adiposity status and changes in early to mid-adulthood with incidence of Alzheimer’s disease. Am. J. Epidemiol.168, 1179–1189 (2008).
   PubMed Web of Science ®Google Scholar
• Hassing LB, Dahl AK, Thorvaldsson V et al. Overweight in midlife and risk of dementia: a 40-year follow-up study. Int. J. Obes. (Lond.)33, 893–898 (2009).
   PubMed Web of Science ®Google Scholar
• Fitzpatrick AL, Kuller LH, Lopez OL et al. Midlife and late-life obesity and the risk of dementia: the Cardiovascular Health Study. Arch. Neurol.66, 336–342 (2009).
   PubMed Web of Science ®Google Scholar
• Gustafson DR, Bäckman K, Waern M et al. Adiposity indicators and dementia over 32 years in Sweden. Neurology73, 1559–1566 (2009).
   PubMedGoogle Scholar
• Atti AR, Palmer K, Volpato S, Winblad B, De Ronchi D, Fratiglioni L. Late-life body mass index and dementia incidence: nine-year follow-up data from the Kungsholmen Project. J. Am. Geriatr. Soc.56, 111–116 (2008).
   PubMed Web of Science ®Google Scholar
• Beydoun MA, Beydoun HA, Wang Y. Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta-analysis. Obes. Rev.9, 204–218 (2008).
   PubMed Web of Science ®Google Scholar
• Profenno LA, Porsteinsson AP, Faraone SV. Meta-analysis of Alzheimer’s disease risk with obesity, diabetes, and related disorders. Biol. Psychiatry67, 505–512 (2010).
   PubMed Web of Science ®Google Scholar
• Gustafson D. A life course of adiposity and dementia. Eur. J. Pharmacol.585, 163–175 (2008).
   PubMed Web of Science ®Google Scholar
• Solomon A, Kivipelto M. Cholesterol-modifying strategies for Alzheimer’s disease. Expert Rev. Neurother.9, 695–709 (2009).
   PubMed Web of Science ®Google Scholar
• Anstey KJ, Lipnicki DM, Low LF. Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am. J. Geriatr. Psychiatry16, 343–354 (2008).
   PubMed Web of Science ®Google Scholar
• Stewart R, White LR, Xue QL, Launer LJ. Twenty-six-year change in total cholesterol levels and incident dementia: the Honolulu-Asia Aging Study. Arch. Neurol.64, 103–107 (2007).
   PubMed Web of Science ®Google Scholar
• Reitz C, Tang MX, Schupf N, Manly JJ, Mayeux R, Luchsinger JA. Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease. Arch. Neurol.67, 1491–1497 (2010).
   PubMedGoogle Scholar
• Scarmeas N, Stern Y, Mayeux R, Luchsinger JA. Mediterranean diet, Alzheimer disease, and vascular mediation. Arch. Neurol.63, 1709–1717 (2006).
   PubMed Web of Science ®Google Scholar
• Féart C, Samieri C, Rondeau V et al. Adherence to a Mediterranean diet, cognitive decline, and risk of dementia. JAMA302, 638–648 (2009).
   PubMed Web of Science ®Google Scholar
• Gu Y, Nieves JW, Stern Y, Luchsinger JA, Scarmeas N. Food combination and Alzheimer disease risk: a protective diet. Arch. Neurol.67, 699–706 (2010).
   PubMed Web of Science ®Google Scholar
• Fotuhi M, Mohassel P, Yaffe K. Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association. Nat. Clin. Pract. Neurol.5, 140–152 (2009).
   PubMedGoogle Scholar
• Devore EE, Grodstein F, van Rooij FJ et al. Dietary intake of fish and omega-3 fatty acids in relation to long-term dementia risk. Am. J. Clin. Nutr.90, 170–176 (2009).
   PubMed Web of Science ®Google Scholar
• Kröger E, Verreault R, Carmichael PH et al. Omega-3 fatty acids and risk of dementia: the Canadian Study of Health and Aging. Am. J. Clin. Nutr.90, 184–192 (2009).
   PubMed Web of Science ®Google Scholar
• Luchsinger JA, Mayeux R. Dietary factors and Alzheimer’s disease. Lancet Neurol.3, 579–587 (2004).
   PubMed Web of Science ®Google Scholar
• Luchsinger JA, Tang MX, Miller J, Green R, Mayeux R. Relation of higher folate intake to lower risk of Alzheimer disease in the elderly. Arch. Neurol.64(1), 86–92 (2007).
   PubMed Web of Science ®Google Scholar
• Luchsinger JA, Tang MX, Miller J, Green R, Mayeux R. Higher folate intake is related to lower risk of Alzheimer’s disease in the elderly. J. Nutr. Health Aging12, 648–650 (2008).
   PubMedGoogle Scholar
• Hooshmand B, Solomon A, Kåreholt I et al. Homocysteine and holotranscobalamin and the risk of Alzheimer disease: a longitudinal study. Neurology75, 1408–1414 (2010).
   PubMed Web of Science ®Google Scholar
• Malouf R, Evans JG. Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people. Cochrane Database Syst. Rev.CD004514 (2008).
   Google Scholar
• van Dam F, van Gool WA. Hyperhomocysteinemia and Alzheimer’s disease: a systematic review. Arch. Gerontol.Geriatr.48, 425–430 (2009).
   PubMedGoogle Scholar
• Isaac MG, Quinn R, Tabet N. Vitamin E for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst. Rev.352(23), 2379–2388 (2008).
   Google Scholar
• Kopf D, Frölich L. Risk of incident Alzheimer’s disease in diabetic patients: a systematic review of prospective trials. J. Alzheimers Dis.16, 677–685 (2009).
   PubMed Web of Science ®Google Scholar
• Lu FP, Lin KP, Kuo HK. Diabetes and the risk of multi-system aging phenotypes: a systematic review and meta-analysis. PLoS One4, e4144 (2009).
   PubMed Web of Science ®Google Scholar
• Xu W, Qiu C, Gatz M, Pedersen NL, Johansson B, Fratiglioni L. Mid- and late-life diabetes in relation to the risk of dementia: a population-based twin study. Diabetes58, 71–77 (2009).
   PubMed Web of Science ®Google Scholar
• Xu W, Qiu C, Winblad B, Fratiglioni L. The effect of borderline diabetes on the risk of dementia and Alzheimer’s disease. Diabetes56, 211–216 (2007).
   PubMed Web of Science ®Google Scholar
• Xu W, Caracciolo B, Wang HX et al. Accelerated progression from mild cognitive impairment to dementia in people with diabetes. Diabetes59, 2928–2935 (2010).
   PubMed Web of Science ®Google Scholar
• Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with Type 2 diabetes mellitus. JAMA301, 1565–1572 (2009).
   PubMed Web of Science ®Google Scholar
• Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ. Early inflammation and dementia: a 25-year follow-up of the Honolulu–Asia Aging Study. Ann. Neurol.52, 168–174 (2002).
   PubMed Web of Science ®Google Scholar
• van Exel E, Eikelenboom P, Comijs H et al. Vascular factors and markers of inflammation in offspring with a parental history of late-onset Alzheimer disease. Arch. Gen. Psychiatry66, 1263–1270 (2009).
   PubMed Web of Science ®Google Scholar
• Engelhart MJ, Geerlings MI, Meijer J et al. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study. Arch. Neurol.61, 668–672 (2004).
   PubMed Web of Science ®Google Scholar
• Tan ZS, Beiser AS, Vasan RS et al. Inflammatory markers and the risk of Alzheimer disease: the Framingham study. Neurology68, 1902–1908 (2007).
   PubMed Web of Science ®Google Scholar
• Sundelöf J, Kilander L, Helmersson J et al. Systemic inflammation and the risk of Alzheimer’s disease and dementia: a prospective population-based study. J. Alzheimers Dis.18(1), 79–87 (2009).
   PubMed Web of Science ®Google Scholar
• Muller M, Tang MX, Schupf N, Manly JJ, Mayeux R, Luchsinger JA. Metabolic syndrome and dementia risk in a multiethnic elderly cohort. Dement. Geriatr. Cogn. Disord.24, 185–192 (2007).
   PubMed Web of Science ®Google Scholar
• Raffaitin C, Gin H, Empana JP et al. Metabolic syndrome and risk for incident Alzheimer’s disease or vascular dementia: the Three-City Study. Diabetes Care32, 169–174 (2009).
   PubMed Web of Science ®Google Scholar
• Forti P, Pisacane N, Rietti E et al. Metabolic syndrome and risk of dementia in older adults. J. Am. Geriatr. Soc.58, 487–492 (2010).
   PubMed Web of Science ®Google Scholar
• Vanhanen M, Koivisto K, Moilanen L et al. Association of metabolic syndrome with Alzheimer disease: a population-based study. Neurology67, 843–847 (2006).
   PubMed Web of Science ®Google Scholar
• Solfrizzi V, Scafato E, Capurso C et al. Metabolic syndrome and the risk of vascular dementia: the Italian Longitudinal Study on Ageing. J. Neurol. Neurosurg. Psychiatry81, 433–440 (2010).
   PubMedGoogle Scholar
• Luchsinger JA, Gustafson DR. Adiposity, Type 2 diabetes, and Alzheimer’s disease. J. Alzheimers Dis.16, 693–704 (2009).
   PubMed Web of Science ®Google Scholar
• van Oijen M, de Jong FJ, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM. Atherosclerosis and risk for dementia. Ann. Neurol.61, 403–410 (2007).
   PubMedGoogle Scholar
• Laurin D, Masaki KH, White LR, Launer LJ. Ankle-to-brachial index and dementia: the Honolulu–Asia Aging Study. Circulation116, 2269–2274 (2007).
   PubMedGoogle Scholar
• Elias MF, Robbins MA, Budge MM, Abhayaratna WP, Dore GA, Elias PK. Arterial pulse wave velocity and cognition with advancing age. Hypertension53, 668–673 (2009).
   PubMed Web of Science ®Google Scholar
• Wendell CR, Zonderman AB, Metter EJ, Najjar SS, Waldstein SR. Carotid intimal medial thickness predicts cognitive decline among adults without clinical vascular disease. Stroke40, 3180–3185 (2009).
   PubMed Web of Science ®Google Scholar
• Sander K, Bickel H, Förstl H et al. Carotid- intima media thickness is independently associated with cognitive decline: the INVADE study. Int. J. Geriatr. Psychiatry25, 389–394 (2010).
   PubMed Web of Science ®Google Scholar
• Vidal JS, Sigurdsson S, Jonsdottir MK et al. Coronary artery calcium, brain function and structure: the AGES-Reykjavik Study. Stroke41, 891–897 (2010).
   PubMedGoogle Scholar
• Ikram MA, van Oijen M, de Jong FJ et al. Unrecognized myocardial infarction in relation to risk of dementia and cerebral small vessel disease. Stroke39, 1421–1426 (2008).
   PubMed Web of Science ®Google Scholar
• Bursi F, Rocca WA, Killian JM et al. Heart disease and dementia: a population-based study. Am. J. Epidemiol.163, 135–141 (2006).
   PubMedGoogle Scholar
• Qiu C, Winblad B, Marengoni A, Klarin I, Fastbom J, Fratiglioni L. Heart failure and risk of dementia and Alzheimer disease: a population-based cohort study. Arch. Intern. Med.166, 1003–1008 (2006).
   PubMed Web of Science ®Google Scholar
• Newman AB, Fitzpatrick AL, Lopez O et al. Dementia and Alzheimer’s disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. J. Am. Geriatr. Soc.53, 1101–1107 (2005).
   PubMed Web of Science ®Google Scholar
• Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol.8, 1006–1018 (2009).
   PubMed Web of Science ®Google Scholar
• Savva GM, Stephan BCM. Epidemiological studies of the effect of stroke on incident dementia: a systematic review. Stroke41, E41–E46 (2010).
   PubMed Web of Science ®Google Scholar
• Purandare N, Burns A, Daly KJ et al. Cerebral emboli as a potential cause of Alzheimer’s disease and vascular dementia: case–control study. BMJ332, 1119–1122 (2006).
   PubMedGoogle Scholar
• Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology64, 277–281 (2005).
   PubMed Web of Science ®Google Scholar
• Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology65, 545–551 (2005).
   PubMed Web of Science ®Google Scholar
• Qiu C, Xu W, Winblad B, Fratiglioni L. Vascular risk profiles for dementia and Alzheimer’s disease in very old people: a population-based longitudinal study. J. Alzheimers Dis.20, 293–300 (2010).
   PubMed Web of Science ®Google Scholar
• Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol.5, 735–741 (2006).
   PubMed Web of Science ®Google Scholar
• Barnes DE, Covinsky K, Whitmer RA, Kuller LH, Lopez OL, Yaffe K. Predicting risk of dementia in older adults: the late-life dementia risk index. Neurology73, 173–179 (2009).
   PubMed Web of Science ®Google Scholar
• Reitz C, Tang MX, Schupf N, Manly JJ, Mayeux R, Luchsinger JA. A summary risk score for the prediction of Alzheimer disease in elderly persons. Arch. Neurol.67, 835–841 (2010).
   PubMedGoogle Scholar
• Deschaintre Y, Richard F, Leys D, Pasquier F. Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology73, 674–680 (2009).
   PubMed Web of Science ®Google Scholar
• Li J, Wang YJ, Zhang M et al. Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology76, 1485–1491 (2011).
   PubMed Web of Science ®Google Scholar
• Greenberg SM, Vernooij MW, Cordonnier C et al. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol.8, 165–174 (2009).
   PubMed Web of Science ®Google Scholar
• Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol.9, 689–701 (2010).
   PubMed Web of Science ®Google Scholar
• Vernooij MW, van der Lugt A, Ikram MA et al. Prevalence and risk factors of cerebral microbleeds: the Rotterdam Scan Study. Neurology70, 1208–1214 (2008).
   PubMed Web of Science ®Google Scholar
• Vermeer SE, Longstreth WT Jr, Koudstaal PJ. Silent brain infarcts: a systematic review. Lancet Neurol.6, 611–619 (2007).
   PubMed Web of Science ®Google Scholar
• Qiu C, Cotch MF, Sigurdsson S et al. Retinal and cerebral microvascular signs and diabetes: the Age, Gene/Environment Susceptibility – Reykjavik Study. Diabetes57, 1645–1650 (2008).
   PubMedGoogle Scholar
• Hajjar I, Quach L, Yang F et al. Hypertension, white matter hyperintensities, and concurrent impairments in mobility, cognition, and mood: the Cardiovascular Health Study. Circulation123, 858–865 (2011).
   PubMed Web of Science ®Google Scholar
• Troncoso JC, Zonderman AB, Resnick SM, Crain B, Pletnikova O, O’Brien RJ. Effect of infarcts on dementia in the Baltimore Longitudinal Study of Aging. Ann. Neurol.64, 168–176 (2008).
   PubMed Web of Science ®Google Scholar
• Honig LS, Tang MX, Albert S et al. Stroke and the risk of Alzheimer disease. Arch. Neurol.60, 1707–1712 (2003).
   PubMedGoogle Scholar
• Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ341, c3666 (2010).
   PubMed Web of Science ®Google Scholar
• Debette S, Beiser A, DeCarli C et al. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study. Stroke41, 600–606 (2010).
   PubMed Web of Science ®Google Scholar
• Silbert LC, Howieson DB, Dodge H, Kaye JA. Cognitive impairment risk: white matter hyperintensity progression matters. Neurology73, 120–125 (2009).
   PubMed Web of Science ®Google Scholar
• van Dijk EJ, Prins ND, Vrooman HA, Hofman A, Koudstaal PJ, Breteler MM. Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: the Rotterdam Scan study. Stroke39, 2712–2719 (2008).
   PubMed Web of Science ®Google Scholar
• Esiri M, Nagy Z, Smith MZ, Barnetson L, Smith AD. Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer’s disease. Lancet354, 919–920 (1999).
   PubMed Web of Science ®Google Scholar
• Ahtiluoto S, Polvikoski T, Peltonen M et al. Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology75, 1195–1202 (2010).
   PubMed Web of Science ®Google Scholar
• Dolan H, Crain B, Troncoso J, Resnick SM, Zonderman AB, Obrien RJ. Atherosclerosis, dementia, and Alzheimer’s disease in the BLSA cohort. Ann. Neurol.68, 231–240 (2010).
   PubMed Web of Science ®Google Scholar
• Wharton SB, Brayne C, Savva GM et al. Epidemiological neuropathology: the MRC Cognitive Function and Aging Study experience. J. Alzheimers Dis.25, 359–372 (2011).
   PubMedGoogle Scholar
• Roher AE, Esh C, Kokjohn TA et al. Circle of Willis atherosclerosis is a risk factor for sporadic Alzheimer’s disease. Arterioscler. Thromb. Vasc. Biol.23, 2055–2062 (2003).
   PubMed Web of Science ®Google Scholar
• Casserly I, Topol E. Convergence of atherosclerosis and Alzheimer’s disease: inflammation, cholesterol, and misfolded proteins. Lancet363, 1139–1146 (2004).
   PubMed Web of Science ®Google Scholar
• Honig LS, Kukull W, Mayeux R. Atherosclerosis and AD: analysis of data from the US National Alzheimer’s Coordinating Center. Neurology64, 494–500 (2005).
   PubMed Web of Science ®Google Scholar
• Gosche KM, Mortimer JA, Smith CD, Markesbery WR, Snowdon DA. Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study. Neurology58, 1476–1482 (2002).
   PubMed Web of Science ®Google Scholar
• Barkhof F, Polvikoski TM, van Straaten EC et al. The significance of medial temporal lobe atrophy: a postmortem MRI study in the very old. Neurology69, 1521–1527 (2007).
   PubMedGoogle Scholar
• Jagust WJ, Zheng L, Harvey DJ et al. Neuropathological basis of magnetic resonance images in aging and dementia. Ann. Neurol.63, 72–80 (2008).
   PubMed Web of Science ®Google Scholar
• Peila R, Rodriguez B, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes51, 1256–1262 (2002).
   PubMed Web of Science ®Google Scholar
• Korf ES, White LR, Scheltens P, Launer LJ. Midlife blood pressure and the risk of hippocampal atrophy: the Honolulu Asia Aging Study. Hypertension44, 29–34 (2004).
   PubMed Web of Science ®Google Scholar
• Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol.5, 64–74 (2006).
   PubMed Web of Science ®Google Scholar
• Launer LJ, Petrovitch H, Ross GW, Markesbery W, White LR. AD brain pathology: vascular origins? Results from the HAAS autopsy study. Neurobiol. Aging29, 1587–1590 (2008).
   PubMedGoogle Scholar
• van Elderen SG, de Roos A, de Craen A et al. Progression of brain atrophy and cognitive decline in diabetes mellitus: a 3-year follow-up. Neurology75, 997–1002 (2010).
   PubMedGoogle Scholar
• Reitz C, Bos MJ, Hofman A, Koudstaal PJ, Breteler MM. Prestroke cognitive performance, incident stroke, and risk of dementia: the Rotterdam Study. Stroke39, 36–41 (2008).
   PubMed Web of Science ®Google Scholar
• Firbank MJ, Burton EJ, Barber R et al. Medial temporal atrophy rather than white matter hyperintensities predict cognitive decline in stroke survivors. Neurobiol. Aging28, 1664–1669 (2007).
   PubMed Web of Science ®Google Scholar
• Fournier A, Oprisiu-Fournier R, Serot JM et al. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Rev. Neurother.9, 1413–1431 (2009).
   PubMed Web of Science ®Google Scholar
• Shah K, Qureshi SU, Johnson M, Parikh N, Schulz PE, Kunik ME. Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. Am. J. Geriatr. Pharmacother.7, 250–261 (2009).
   PubMedGoogle Scholar
• Duron E, Hanon O. Antihypertensive treatments, cognitive decline, and dementia. J. Alzheimers Dis.20, 903–914 (2010).
   PubMedGoogle Scholar
• Peila R, White LR, Masaki K, Petrovitch H, Launer LJ. Reducing the risk of dementia: efficacy of long-term treatment of hypertension. Stroke37, 1165–1170 (2006).
   PubMed Web of Science ®Google Scholar
• Haag MD, Hofman A, Koudstaal PJ, Breteler MM, Stricker BH. Duration of antihypertensive drug use and risk of dementia: a prospective cohort study. Neurology72, 1727–1734 (2009).
   PubMed Web of Science ®Google Scholar
• Li NC, Lee A, Whitmer RA et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ340, B5465 (2010).
   PubMed Web of Science ®Google Scholar
• Hoffman LB, Schmeidler J, Lesser GT et al. Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. Neurology72, 1720–1726 (2009).
   PubMed Web of Science ®Google Scholar
• Forette F, Seux ML, Staessen JA et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch. Intern. Med.162, 2046–2052 (2002).
   PubMed Web of Science ®Google Scholar
• Tzourio C, Anderson C, Chapman N et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch. Intern. Med.163, 1069–1075 (2003).
   PubMed Web of Science ®Google Scholar
• Peters R, Beckett N, Forette F et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol.7, 683–689 (2008).
   PubMed Web of Science ®Google Scholar
• Anderson C, Teo K, Gao P et al. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol.10, 43–53 (2011).
   PubMed Web of Science ®Google Scholar
• McGuinness B, Todd S, Passmore P, Bullock R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst. Rev.CD004034 (2009).
   PubMedGoogle Scholar
• Lithell H, Hansson L, Skoog I et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J. Hypertens.21, 875–886 (2003).
   PubMed Web of Science ®Google Scholar
• Staessen JA, Thijs L, Richart T, Odili AN, Birkenhäger WH. Placebo-controlled trials of blood pressure-lowering therapies for primary prevention of dementia. Hypertension57, E6–E7 (2011).
   PubMed Web of Science ®Google Scholar
• Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer’s disease: systematic review and meta-analysis of observational studies. BMJ327, 128 (2003).
   PubMed Web of Science ®Google Scholar
• Szekely CA, Zandi PP. Non-steroidal anti-inflammatory drugs and Alzheimer’s disease: the epidemiological evidence. CNS Neurol. Disord.9, 132–139 (2010).
   PubMed Web of Science ®Google Scholar
• Arvanitakis Z, Grodstein F, Bienias JL et al. Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology70, 2219–2225 (2008).
   PubMed Web of Science ®Google Scholar
• Lyketsos CG, Breitner JC, Green RC et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology68, 1800–1808 (2007).
   PubMed Web of Science ®Google Scholar
• Martin BK, Szekely C, Brandt J et al. Cognitive function over time in the Alzheimer’s disease anti-inflammatory prevention trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch. Neurol.65, 896–905 (2008).
   PubMed Web of Science ®Google Scholar
• Sonnen JA, Larson EB, Walker RL et al. Nonsteroidal anti-inflammatory drugs are associated with increased neuritic plaques. Neurology75, 1203–1210 (2010).
   PubMed Web of Science ®Google Scholar
• Meinert CL, Breitner JC. Chronic disease long-term drug prevention trials: lessons from the Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT). Alzheimers Dement.4(1 Suppl. 1), S7–S14 (2008).
   PubMed Web of Science ®Google Scholar
• Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA279, 688–695 (1998).
   PubMed Web of Science ®Google Scholar
• Craig MC, Murphy DG. Estrogen therapy and Alzheimer’s dementia. Ann. NY Acad. Sci.1205, 245–253 (2010).
   PubMedGoogle Scholar
• Shumaker SA, Legault C, Rapp SR et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA289, 2651–2662 (2003).
   PubMed Web of Science ®Google Scholar
• Shumaker SA, Legault C, Kuller L et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study. JAMA291, 2947–2958 (2004).
   PubMed Web of Science ®Google Scholar
• Whitmer RA, Quesenberry CP, Zhou J, Yaffe K. Timing of hormone therapy and dementia: the critical window theory revisited. Ann. Neurol.69, 163–169 (2011).
   PubMed Web of Science ®Google Scholar
• Hogervorst E, Yaffe K, Richards M, Huppert FA. Hormone replacement therapy to maintain cognitive function in women with dementia. Cochrane Database Syst. Rev.CD003799 (2009).
   PubMedGoogle Scholar
• Rodriguez EG, Dodge HH, Birzescu MA, Stoehr GP, Ganguli M. Use of lipid-lowering drugs in older adults with and without dementia: a community-based epidemiological study. J. Am. Geriatr. Soc.50, 1852–1856 (2002).
   PubMed Web of Science ®Google Scholar
• Li G, Larson EB, Sonnen JA et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology69, 878–885 (2007).
   PubMed Web of Science ®Google Scholar
• Arvanitakis Z, Schneider JA, Wilson RS et al. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology70, 1795–1802 (2008).
   PubMed Web of Science ®Google Scholar
• McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst. Rev.CD003160 (2009).
   PubMedGoogle Scholar
• McGuinness B, O’Hare J, Craig D, Bullock R, Malouf R, Passmore P. Statins for the treatment of dementia. Cochrane Database Syst. Rev.CD007514 (2010).
   PubMedGoogle Scholar
• Feldman HH, Doody RS, Kivipelto M et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology74, 956–964 (2010).
   PubMed Web of Science ®Google Scholar
• DeKosky ST, Williamson JD, Fitzpatrick AL et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA300, 2253–2262 (2008).
   PubMed Web of Science ®Google Scholar
• Snitz BE, O’Meara ES, Carlson MC et al. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA302, 2663–2670 (2009).
   PubMed Web of Science ®Google Scholar
• Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst. Rev.CD003120 (2009).
   PubMedGoogle Scholar
• Weinmann S, Roll S, Schwarzbach C, Vauth C, Willich SN. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr.10, 14 (2010).
   PubMed Web of Science ®Google Scholar
• Janssen IM, Sturtz S, Skipka G, Zentner A, Garrido MV, Busse R. Ginkgo biloba in Alzheimer’s disease: a systematic review. Wien. Med. Wochenschr.160, 539–546 (2010).
   PubMedGoogle Scholar
• Daviglus ML, Bell CC, Berrettini W et al. National Institutes of Health State-of-the-Science Conference Statement: preventing Alzheimer disease and cognitive decline. Ann. Intern. Med.153, 176–181 (2010).
   PubMed Web of Science ®Google Scholar
• Viswanathan A, Rocca WA, Tzourio C. Vascular risk factors and dementia: how to move forward? Neurology72, 368–374 (2009).
   PubMed Web of Science ®Google Scholar
• Qiu C, Kivipelto M, Fratiglioni L. Preventing Alzheimer disease and cognitive decline. Ann. Intern. Med.154, 211 (2011).
   PubMedGoogle Scholar
• Li G, Shofer JB, Rhew IC et al. Age-varying association between statin use and incident Alzheimer’s disease. J. Am. Geriatr. Soc.58, 1311–1317 (2010).
   PubMed Web of Science ®Google Scholar
• Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C. Age, neuropathology, and dementia. N. Engl. J. Med.360, 2302–2309 (2009).
   PubMed Web of Science ®Google Scholar
• Whitlock G, Lewington S, Sherliker P et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet373, 1083–1096 (2009).
   PubMed Web of Science ®Google Scholar
• Whalley LJ, Dick FD, McNeill G. A life-course approach to the aetiology of late-onset dementias. Lancet Neurol.5, 87–96 (2006).
   PubMed Web of Science ®Google Scholar
• Ritchie K, Carrière I, Ritchie CW, Berr C, Artero S, Ancelin ML. Designing prevention programmes to reduce incidence of dementia: prospective cohort study of modifiable risk factors. BMJ341, c3885 (2010).
   PubMed Web of Science ®Google Scholar
• Middleton LE, Yaffe K. Promising strategies for the prevention of dementia. Arch. Neurol.66, 1210–1215 (2009).
   PubMed Web of Science ®Google Scholar
• Fratiglioni L, Qiu C. Prevention of cognitive decline in ageing: dementia as the target, delayed onset as the goal. Lancet Neurol.10, 778–779 (2011).
   PubMedGoogle Scholar
• Vellas B, Andrieu S, Sampaio C, Coley N, Wilcock G. Endpoints for trials in Alzheimer’s disease: a European task force consensus. Lancet Neurol.7, 436–450 (2008).
   PubMed Web of Science ®Google Scholar
• Aisen PS, Andrieu S, Sampaio C et al. Report of the task force on designing clinical trials in early (predementia) AD. Neurology76, 280–286 (2011).
   PubMed Web of Science ®Google Scholar